These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 21423645

  • 1. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.
    Cajas-Monson LC, Mkocha H, Muñoz B, Quinn TC, Gaydos CA, West SK.
    PLoS Negl Trop Dis; 2011 Mar 15; 5(3):e978. PubMed ID: 21423645
    [Abstract] [Full Text] [Related]

  • 2. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania.
    West SK, Munoz B, Mkocha H, Gaydos CA, Quinn TC.
    J Infect Dis; 2011 Jul 15; 204(2):268-73. PubMed ID: 21673038
    [Abstract] [Full Text] [Related]

  • 3. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK, Munoz B, Mkocha H, Holland MJ, Aguirre A, Solomon AW, Foster A, Bailey RL, Mabey DC.
    Lancet; 2005 Oct 08; 366(9493):1296-300. PubMed ID: 16214600
    [Abstract] [Full Text] [Related]

  • 4. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK, Munoz B, Mkocha H, Gaydos C, Quinn T.
    Invest Ophthalmol Vis Sci; 2007 Apr 08; 48(4):1492-7. PubMed ID: 17389476
    [Abstract] [Full Text] [Related]

  • 5. Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial.
    Amza A, Kadri B, Nassirou B, Stoller NE, Yu SN, Zhou Z, Chin S, West SK, Bailey RL, Mabey DC, Keenan JD, Porco TC, Lietman TM, Gaynor BD, PRET Partnership.
    PLoS Negl Trop Dis; 2012 Apr 08; 6(4):e1586. PubMed ID: 22545165
    [Abstract] [Full Text] [Related]

  • 6. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK, Moncada J, Munoz B, Mkocha H, Storey P, Hardick J, Gaydos CA, Quinn TC, Schachter J.
    J Infect Dis; 2014 Jul 01; 210(1):65-71. PubMed ID: 24446528
    [Abstract] [Full Text] [Related]

  • 7. Mass treatment with single-dose azithromycin for trachoma.
    Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, Natividad-Sancho A, Molina S, Safari S, Shao JF, Courtright P, Peeling RW, West SK, Bailey RL, Foster A, Mabey DC.
    N Engl J Med; 2004 Nov 04; 351(19):1962-71. PubMed ID: 15525721
    [Abstract] [Full Text] [Related]

  • 8. Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.
    Yohannan J, He B, Wang J, Greene G, Schein Y, Mkocha H, Munoz B, Quinn TC, Gaydos C, West SK.
    Invest Ophthalmol Vis Sci; 2014 Jun 06; 55(7):4144-50. PubMed ID: 24906862
    [Abstract] [Full Text] [Related]

  • 9. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
    Ramadhani AM, Derrick T, Macleod D, Massae P, Malisa A, Mbuya K, Mtuy T, Makupa W, Roberts CH, Bailey RL, Mabey DCW, Holland MJ, Burton MJ.
    PLoS Negl Trop Dis; 2019 Jul 06; 13(7):e0007559. PubMed ID: 31306419
    [Abstract] [Full Text] [Related]

  • 10. Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in Tanzania.
    Campbell JP, Mkocha H, Munoz B, West SK.
    Ophthalmic Epidemiol; 2012 Feb 06; 19(1):38-42. PubMed ID: 22273357
    [Abstract] [Full Text] [Related]

  • 11. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.
    Biebesheimer JB, House J, Hong KC, Lakew T, Alemayehu W, Zhou Z, Moncada J, Rogér A, Keenan J, Gaynor BD, Schachter J, Lietman TM.
    Ophthalmology; 2009 Nov 06; 116(11):2047-50. PubMed ID: 19744717
    [Abstract] [Full Text] [Related]

  • 12. Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment.
    Gower EW, Solomon AW, Burton MJ, Aguirre A, Muñoz B, Bailey R, Holland M, Makalo P, Massae P, Mkocha H, Mabey DC, West SK.
    Invest Ophthalmol Vis Sci; 2006 Nov 06; 47(11):4767-71. PubMed ID: 17065486
    [Abstract] [Full Text] [Related]

  • 13. Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities.
    Burton MJ, Holland MJ, Makalo P, Aryee EA, Sillah A, Cohuet S, Natividad A, Alexander ND, Mabey DC, Bailey RL.
    PLoS Negl Trop Dis; 2010 Oct 05; 4(10):. PubMed ID: 20957147
    [Abstract] [Full Text] [Related]

  • 14. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
    Morberg DP, Alemayehu W, Melese M, Lakew T, Sisay A, Zhou Z, Cevallos V, Oldenburg CE, Porco TC, Lietman TM, Keenan JD.
    Ophthalmic Epidemiol; 2019 Feb 05; 26(1):19-26. PubMed ID: 30153085
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
    Wilson N, Goodhew B, Mkocha H, Joseph K, Bandea C, Black C, Igietseme J, Munoz B, West SK, Lammie P, Kasubi M, Martin DL.
    Ophthalmic Epidemiol; 2019 Feb 05; 26(1):1-6. PubMed ID: 30543311
    [Abstract] [Full Text] [Related]

  • 16. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
    Harding-Esch EM, Holland MJ, Schémann JF, Sillah A, Sarr B, Christerson L, Pickering H, Molina-Gonzalez S, Sarr I, Andreasen AA, Jeffries D, Grundy C, Mabey DCW, Herrmann B, Bailey RL.
    Parasit Vectors; 2019 Oct 22; 12(1):497. PubMed ID: 31640755
    [Abstract] [Full Text] [Related]

  • 17. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J, Munoz B, Mkocha H, Gaydos CA, Bailey R, Lietman TA, Quinn T, West SK.
    JAMA Ophthalmol; 2013 Apr 22; 131(4):431-6. PubMed ID: 23392481
    [Abstract] [Full Text] [Related]

  • 18. Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?
    West SK, Stare D, Mkocha H, Munoz B, Gaydos C, Quinn TC.
    Invest Ophthalmol Vis Sci; 2011 Jul 29; 52(8):6040-2. PubMed ID: 21680866
    [Abstract] [Full Text] [Related]

  • 19. Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania.
    Broman AT, Shum K, Munoz B, Duncan DD, West SK.
    Invest Ophthalmol Vis Sci; 2006 Jan 29; 47(1):99-104. PubMed ID: 16384950
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial of high dose azithromycin compared to standard dosing for children with severe trachoma in Tanzania.
    Campbell JP, Mkocha H, Munoz B, West SK.
    Ophthalmic Epidemiol; 2009 Jan 29; 16(3):175-80. PubMed ID: 19437312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.